Phase 2 RCT of intravitreal sirolimus versus anti-VEGF for wet AMD with prior treatment failure
This Phase 2 randomized controlled trial compared intravitreal sirolimus injections to anti-VEGF treatment in patients with wet age-related macular degeneration who had persistent retinal edema despite previous anti-VEGF therapy. The study was conducted at a single site with subject masking. Specific efficacy and safety results were not reported in the abstract provided.
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Jun 22, 2017 · Discovered: Sep 19, 2026 · Assessed: — · Research update
What it does not prove
- Limitations have not yet been verified. Read the primary source.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- —
- Population
- Subjects with wet Age-Related Macular Degeneration (wet AMD) with persistent intraretinal or subretinal edema due to neovascular AMD despite previous AntiVEGF treatment
- Primary outcome
- Safety and efficacy of intravitreal injections of Sirolimus in wet AMD with persistent edema
- Effect size
- —
- Significance
- Not reported
- Journal
- Maturi, Raj K., M.D., P.C.
- Published
- Jun 22, 2017
Sources
Primary source
- Maturi, Raj K., M.D., P.C. ↗Clinical trial
Source versions
Assessment history
9/24/2026 · SUPERSEDED: Source updated; assessment withdrawn pending review.
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
No comments yet
Be the first to weigh in on this evidence.